Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium

Keyphrases

• Hematopoietic Cell Transplantation 100%
• Cell Therapy 100%
• Pediatric Transplant 100%
• Transplantation Therapy 100%
• Congenital Dyserythropoietic Anemia 100%
• 95% Confidence Interval 27%
• Graft-versus-host Disease (GvHD) 18%
• Viral Reactivation 18%
• Event-free Survival 18%
• Chronic Graft-versus-host Disease (cGVHD) 18%
• Transplantation 9%
• Anemia 9%
• Comorbidity 9%
• Overall Survival 9%
• Myeloablative 9%
• Bone Marrow 9%
• Univariate Analysis 9%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 9%
• Clinical Information 9%
• GATA1 9%
• Cumulative Incidence 9%
• Graft Failure 9%
• Engraftment 9%
• Descriptive Statistics 9%
• Disease-free 9%
• Free Skin Graft 9%
• Secondary Hemochromatosis 9%
• Iron Overload 9%
• Umbilical Cord Blood 9%
• Venous Disease 9%
• Reduced Intensity 9%
• Nonmyeloablative 9%
• Pediatric Transplantation 9%
• Chelation 9%
• HLA-matched Donor 9%
• Hemolytic Anemia 9%
• Cell-Associated 9%
• Chromosome 20 9%
• Graft Source 9%
• Fludarabine 9%
• Busulfan 9%
• Rare Type 9%
• Haploidentical 9%
• Ineffective Erythropoiesis 9%
• Chelation Therapy 9%
• SEC23B 9%
• Retrospective multicenter Study 9%
• Survival Event 9%
• Unknown Type 9%
• Anemia Types 9%

Medicine and Dentistry

• Pediatrics 100%
• Cell Transplantation 100%
• Cell Therapy 100%
• Congenital Dyserythropoietic Anemia 100%
• Hematopoietic Cell 100%
• Graft Versus Host Reaction 16%
• Event Free Survival 16%
• Anemia 8%
• Overall Survival 8%
• Univariate Analysis 8%
• Graft Failure 8%
• Cumulative Incidence 8%
• Hemochromatosis 8%
• Cord Blood 8%
• Iron Overload 8%
• Engraftment 8%
• Chronic Graft Versus Host Disease 8%
• Acute Graft Versus Host Disease 8%
• Vein Occlusion 8%
• Morbidity 8%
• Hemolytic Anemia 8%
• Chromosome 20 8%
• Fludarabine 8%
• Busulfan 8%
• Ineffective Erythropoiesis 8%
• Transcription Factor GATA 1 8%
• Chelation Therapy 8%
• Congenital Dyserythropoietic Anemia Type II 8%
• Congenital Dyserythropoietic Anemia Type 1 8%
• Comorbidity 8%
• Median Follow Up 8%

Immunology and Microbiology

• Hematopoietic Cell 100%
• Cell Transplantation 100%
• Graft-Versus-Host Disease 16%
• Chelation 16%
• Event Free Survival 16%
• Chronic Graft Versus Host Disease 8%
• Overall Survival 8%
• Engraftment 8%
• Transcription Factor GATA 1 8%
• Acute Graft Versus Host Disease 8%
• Morbidity 8%
• Erythropoiesis 8%
• Umbilical Cord Blood 8%
• Pediatric Transplantation 8%
• Chromosome 20 8%
• Comorbidity 8%